Darou Darman Arang is a fast growing pharmaceutical Company in Iran.

Our Story

We are a fast growing pharmaceutical company manufacturing our own brands and representing  pharmaceutical companies from around the world in Iran to import medicines.

DAROU DARMAN ARANG acts as the representative agent for specialty, rare disease, biotech and vaccine producing companies looking to penetrate to Iran. We are the preferred strategic partner, providing turn-key solutions and support for their commercial operations……  Read more 



We have ensured world-class quality in design, equipment and operations in our manufacturing facility. Our units ensure that we are able to provide best-in-class products to patients across the Iran and emerging markets around. Our manufacturing operations are focused on producing generics and branded generics, in the full range of dosage forms, including tablets, capsules, injectable, pre-filled syringe and freeze dried powder. ……  Read more 


Imports of Finished Pharmaceuticals

As the pioneer of our mission to meet the needs of the health society across IRAN and beyond with our expert staffs and facilities to import different health care products…… Read more 


Research & Development Department

We in R&D department aimed to Reach to various market requirements and high quality products, by representing formulation and providing new method analysis, taking advantage of experienced Experts, using the most up to dated sources of pharmaceuticals and advanced devices. In addition to exploitation of cooperation and consultation of prominent University professors and other authentic science centers.

Read More



Having sufficient knowledge of drug registration rules & regulations for registration of products
Adequately capability of registering new products in the Drug National List
Well knowledge of the drug, raw material and food supplement approval process and registration bureaucracy in Ministry of Health
Submitting registration documents to MOH

Read More


Featured products

Latest news

[ News Archive ]

22 Jun

Biosimilars and the role of regulatory authorities

According to authors Hye-Na Kang and Ivana Knezevic, from the World Health Organization (WHO), market access to biosimilars can be restricted by several factors [1]: 
(i)   manufacturing processes may be expensive and complex
(ii)  patents on the manufacturing processes of the original product may not have expired
(iii) biosimilar manufacturers may have limited access to data on the original product
(iv)  appropriate regulatory frameworks may not be in place
(v)   government policies on switching to biosimilars, pricing and reimbursement may be lacking.

22 Jun

Celltrion resubmits biosimilar trastuzumab to FDA

South Korean biotechnology company Celltrion announced on 18 June 2018 that it had resubmitted its application for marketing approval for its candidate trastuzumab biosimilar, CT‑P6, to the US Food and Drug Administration (FDA).

22 Jun

Developing biosimilars

Global pharmaceutical sales have grown 6.4% over the last five years to reach US$964 billion in 2017. Although the US still accounts for the major share of drug sales other markets are growing fast. In the period 2012−2017 the pharmaceuticals market in China grew at a rate of 10.2%, making it the second biggest market by sales, accounting for US$82 billion in 2017. Brazil also experienced a huge increase in sales with growth of 12.1% during 2012−2017.

Copyright © 2018 Darou Darman Arang Co. All rights reserved.